Home Compliance Novo Nordisk Settles Allegations of Improperly Sourced Injection Needles, for $6.3 Million ComplianceFCANews Novo Nordisk Settles Allegations of Improperly Sourced Injection Needles, for $6.3 Million September 9, 2022 19 Share FacebookLinkedinTwitter ravipat | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Law Trends in GSA’s Multiple Award Schedule Program Compliance DOJ Wants to Hide Why It Spied On Congressional Staff, Whistleblower Groups Fight Back Compliance Berko Extradited To U.S. To Face FCPA Charges